Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Macromoltek Inc. logo — Revolutionizing antibody design

Macromoltek Inc.

Revolutionizing antibody design

Founded 2010 United States Austin, United States 3 employees Seed Total: $1.49M Biopharma, Biotechnology +1

General Information

Company Name Macromoltek Inc.
Founded Year 2010
Location United States Austin, United States
Employees 3
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Seed
Business Model B2B, SaaS, D2C
Revenue Model Service Fee, Project Based, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with Macromoltek Inc.. To contact Macromoltek Inc., visit macromoltek.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Macromoltek Inc. compare?

A PDF of Macromoltek Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Macromoltek Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Macromoltek Inc.

Macromoltek Inc. is making waves in the antibody design sector with its advanced use of computational modeling. Leveraging the power of technology, the company stands by its mission to revolutionize antibody design, as clearly emphasized in their compelling slogan. Founded in 2010, Macromoltek operates within the competitive realms of Biopharma, Biotechnology, and Pharmaceutical industries and is based in the United States.

Their approach allows for rapid antibody creation—turning around custom designs in just a week. This speed does not compromise their precision in solving complex design challenges, humanizing therapeutics, and mapping antigen epitopes.

The company's innovative potential caught the attention of notable investors, securing a $120.00K Seed Round on 22 March 2018, led by industry leader, Y Combinator. This backing not only highlights the startup's scalability but also underscores its promising trajectory in transforming the future of antibody therapeutics.

Business keywords: Antibody Design, Computational Modeling, Custom Antibodies, Drug Discovery, Antibody Therapeutics, Diagnostics, Epitope Mapping, Humanization of Antibodies, Antibody Structure Improvement, Antibody Design Problems, Therapeutic Antibodies, Antibody Modeling, Machine Learning in Biology, Computational Biology, Bioinformatics

Services & Products

AI-Driven Antibody Discovery
Computational Structure Modeling
Custom Antibody Engineering Partnerships

Target Customers

Biotech companies Pharmaceutical companies Research institutions involved in therapeutic antibody development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $120.00K 1
Y Combinator
Y Combinator
22 Mar 2018
Seed Round Undisclosed 2
Neotribe Ventures
Neotribe Ventures, DCVC Bio
01 Jan 2018
Grant $1.19M 1
National Science Foundation
National Science Foundation
20 Aug 2016
Grant $178.70K 1
National Science Foundation
National Science Foundation
15 Jun 2015

Macromoltek Inc. Alternatives & Competitors

View All Alternatives
Macromoltek Inc. vs
MAbSilico
MAbSilico France

The only TechBio providing computationally designed antibodies through AI with biological validation...

14 employees
AI, Biotechnology
Macromoltek Inc. vs
Antiverse
Antiverse United Kingdom

Designing functional antibodies for the most challenging targets.

Series A
34 employees
AI, Biotechnology
Macromoltek Inc. vs
Diffuse Bio
Diffuse Bio

We build generative AI for protein therapeutics.

9 employees
Biotechnology, Pharmaceutical
Also compare with: Macromoltek Inc. vs Biolojic Design, Ltd. Biolojic Design, Ltd. View all alternatives

FAQ About Macromoltek Inc.

Revolutionizing antibody design
Macromoltek Inc. was founded in 2010.
Macromoltek Inc. is headquartered in Austin, United States.
Macromoltek Inc. operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Antibody Design, Computational Modeling, Custom Antibodies and Drug Discovery. Its customers include Biotech companies, Pharmaceutical companies and Research institutions involved in therapeutic antibody development.
Macromoltek Inc. has a B2B, SaaS and D2C business model. Its revenue comes from Service Fee, Project Based and Usage Based.
Macromoltek Inc. has approximately 3 employees.
Macromoltek Inc. has completed 4 funding rounds, raising a total of $1.49M. The latest funding stage is Seed.
Macromoltek Inc. offers: AI-Driven Antibody Discovery, Computational Structure Modeling, Custom Antibody Engineering Partnerships.
Top alternatives and competitors to Macromoltek Inc. include MAbSilico, Antiverse, Diffuse Bio, MOLCURE Inc., Meddenovo Drug Design. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Macromoltek Inc. and MAbSilico are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Macromoltek Inc., https://bouncewatch.com/company/macromoltek-inc, updated 29 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout